

Genetic disorders of Hemoglobin

- The World Health Organization estimates that about 5-7% of world's population carries a clinically significant hemoglobin variant.
- The rate of occurrence of hemoglobinopathies in California is more than 1 in 4,000 births.²
- More than 400 clinically abnormal hemoglobins have been identified and about half are clinically significant

World Health Organization, Sickle-cell disease and other haemoglobin disorders, Jan 2011
 California Department of Health Care Services, Systems of Care Division Child Health and Disability Prevention Program, Health Assessment Guidelines March 2016


KAISER PERMANENTE.

KAISER PERMANENTE.


Hemoglobinopathies in Pregnancy Genetics Different Types of Conditions Clinical Recommendations Counseling

Refer to Genetics


When in doubt, send a Dr. Advice to genetics.



How are hemoglobinopathies passed	l in families?
Autosomal Recessive	
	KAISER PERMANENTE



		•
	Autosomal recessive	
S. K.	Heterozygotes	
NA Par	Hb AS = Sickle cell trait	
	Hb AC = Hemoglobin C trait	
460		-
	Homozygotes Hb SS = sickle cell anemia	
	Hb SC = sickle cell disease	
	Sickle cell is most common people of African ancestry, but also seen in people of Latin- American, Mediterranean and Asian East Indian.	
Y	American, Mediterranean and Asian East Indian.	
	Fing RAISER PERMANENTE	
\\/\langle		
in certain por	oglobinpathies more common oulations?	
iii oortaiii pop	34141101131	
		1
	₩ KAISER PERMANENTE。	
1		1




Heterozygote Advantage	
Carriers of sickle cell trait have red cells that are inhospitable to the malaria organism	S Cistribution of sickle-cell grine project and projec
	in Kaiser Permanente.


Different Types of Inherited Anemias

Hemoglobin molecule \blacksquare Hb A: $\alpha_2\beta_2$ A for "adult" hemoglobin Beta globin gene mutations - Hb S, Hb C, Hb E, etc - Beta thalassemia Alpha globin gene mutations Alpha thalassemia Hb Constant Spring KAISER PERMANENTE. What is a sickle? Inspiring Camp Crescent Moon

Sickle Cell Pathophysiology

- In deoxygenated blood, sickle red cells are only 1/5 as soluble as normal hemoglobin.
- Under conditions of low oxygen tension, Hb S molecules aggregate into rod shape polymers that distort the round shape of a red cell.
- These misshapen 'sickle' cells are less flexible than normal and cannot squeeze single file through capillaries, blocking blood flow and causing ischemia.





	Sicl	de cell trai	t		
CBC NO DIFF Status: Final result Visible to patient: kp.org Nex	t appt: None	Dx: SUPERVISION NORMAL F	FIRST PREGNANCY, F		
Newer results are available. Click to view them no	ow.				
		Ref Range			5 10:03 AM
WBC'S AUTO		4.0 - 11.0 x1000/mcL		4.4	
RBC, AUTO		4.20 - 5.40 Millimol.		4.47	
HGB		12.0 - 16.0 g/dL		13.2	
HCT, AUTO		37.0 - 47.0 %		39.0	
MCV		81.0 - 99.0 ft.		87.2	
MCH		27.0 - 35.0 pg/cell		29.5	
MCHC		32.0 - 37.0 gldL		33.8	
RDW, BLOOD PLATELETS, AUTOMATED COUNT		11.5 - 14.5 %		13.1 157	
TOTICE STATIONARIES COM		130 - 400 x1000/mcL		101	
EMOGLOBIN EVALUATION latus: Final result Visible to patient: Not Released		RVISION NORMAL FIRST PREC	SNANCY, F 1/13/15 10:	02.414	1/13/15 10:03 AI
HEMOGLOBIN F %, HPLC	ret e=2		0.2	U3 AM	1/13/15 10:03 A
HEMOGLOBIN PHENOTYPE, BLOOD			See Confrr	n Test	AS (A)
Narrative					
RMS ACCN: 559357320					
Specimen Collected: 01/13/15 10:03 AM	Last Resulte	d: 01/15/15 1:26 PM	Lab Flowshee	t Order Detail	s View Encounter La
			jing p	AISER PE	RMANENTE.

Sickle Cell Trait Usually does not cause any serious health problems **A KAISER PERMANENTE.**

What is th	e life expectancy for sickle cell anemia?
	45 years
	KAISER PERMANENTE

Sickle Cell Anemia a multisystem disorder Pain crises Due to ischemic tissue from obstructed blood flow, hypoxia and acidosis May last several days to weeks Triggered by fever, dehydration, cold, stress Infection Immune system is compromised because the spleen is not functioning properly or missing. Flu, sepsis, meningitis, pneumonia

Sickle Cell Anemia

a multisystem disorder

- Stroke
 - Ischemic or hemorrhagic lesion in a specific vascular area
- Retinopathy
 - $-% \left(-\right) =\left(-\right) \left(-\right) \left($
- Acute chest syndrome
 - $-\,$ Due to acute pulmonary infarction pneumonia like symptoms
- Splenic Sequestration (enlarged)

KAISER PERMANENTE.

Prevention for Sickle Cell Anemia Routine care Healthy Diet Medications Vaccinations Hydradtion Anti-inflamatory agents Prophylactic antibiotics


Treatment for Sickle Cell Anemia

Anemia treatment
Stroke prevention
Chelation therapy
Pain management



KAISER PERMANENTE.

What are other	hemoglobin variant	s besides			
sickle cell?	ŭ				
			•		
What are other	hemoglobin variants	besides			
sickle cell?	· ·				
Hb C					
Hb E					
Hb D					
Hb O				 	
		KAISER PERMANENTE			
Hb HaSharon	Hb Pisa	Hb Hyde Park			
Hb S - Sickle Hb Hope	Hb G-Phi Hb Tak	ladelphia			
More	than 400 abno	rmal			
hemoglobi	ns have been	described			
Hb Kansas Hb E	Hb N-Baltimore Hb Hammersmith	Hb D - Punjab			
Hb Lepore	Hb O - Arab	Hb C	_	 	
Hb M Hb Gun Hill Hb Constar	Hb Kempsey	Hb Korle-Bu Hb H		 	
TIP GULLLIII DD COUSTAL				 	



Which population has the highest carrier frequency?

Carrier frequencies					
Ethnicity	<u>β thal</u>	<u>α thal</u>	Hb S	Hb C	Other Hb
Mediterranean	1/20-30	1/40	1/40	rare	D, G, lepore
African American	1/75	1/30 trans	1/12	1/50	O,D
African Caribbean	1/50-75	1/30 trans	1/12	1/30	O,D
West-African	1/50	1/30 trans	1/6	1/20-30	O,D
Hispanic Caribbean	1/75	Variable	1/30	rare	Variable
Hispanic Latino	1/30-50	Variable	1/30-200	rare	J,E
Asian	1/50	1/20 cis	Rare	rare	E
Southeast Asian	1/30	1/20 cis	rare	rare C	E 1/2-1/3
Asian Indian	1/30-150	Variable	1/50	rare	D, O, E
Middle Eastern	1/50	Variable	1/50	rare	D, O, E
March of Dimes Genetic Screening Pocket Facts					

Hemoglobin E

- Structural variant resulting in decreased synthesis of hemoglobin.
- Most common structural hemoglobin abnormality in the world
 - About 1/10 Southeast Asians carry Hb E
 - $-\;$ Up to 1/3 carries Hb E $\;$ in parts of Laos, Cambodia, Thailand
 - Up to 1/2 in parts of Northern India
- Homozygous EE mild anemia, often asymptomatic
- $\,\blacksquare\,$ Only a risk for disease when combined with β thal trait


KAISER PERMANENTE


PHEMOGLOBIN VARIANT CONFIRMATION, ELECTROPHORESIS Status: Final result Visible to patient No (Not Released) Next appt 10/23/2017 at 08:00 AM in Obstetrics. Gynecology (KELUE HEMOGLOBIN ABLDON, ELECTROPHORESIS HEMOGLOBIN AZ, TOTAL BLOOD, EP **Comments: The Al reference ranges for patients with select hemoglobin variants: Hgb S 2.2-3.9% Hgb D 2.0-3.6% Hgb E 2.8-4.5% The Alevels are not a specific indicator of an underlying beta-thalassemia in the presence of these hemoglobin variants. HGE 5%, BLOOD, ELECTROPHORESIS HGE S, BLOOD, ELECTROPHORESIS HGE EXECUTEDHORESIS Meterozygous MD Z (MD Z TRAIT). This is a clinically benign condition which produces no anenias. Hematology consultation is not necessary, but reproductive counseling may be advisable. Anenia may indicate the presence of an underlying thalassemia.


Hemoglobin C

- Similar to Hb S
 - (the same DNA position as the sickle cell mutation but different amino acid substitution)
 - Compound heterozygotes (Hb SC) are affected with "SC disease" which varies, but is often a milder anemia than sickle cell disease.
- Oxygenated Hb C tends to crystallize, leading to less flexible red cells and mild hemolysis.
- About 1/30-1/50 African Americans carries Hb C

	_
Hb C trait	
HEMOGLOBIN VARIANT CONFIRMATION, ELECTROPHORESIS Status: Final result: Visible to patient: No (Not Released) Next appt: None Ref Range & Units 12/21/16 11:39 AM HEMOGLOBIN ABLDQN, ELECTROPHORESIS 59.6	
HGR C%_BLOOD_LECTROPHORESIS	
reproductive counseling may be advisable. Asemia, preponderance of TB C and TB F deventions may indicate the presence of an underlying thalassemia. Narrative RMS ACCN: 59855625	
Specimen Collected 12/21/6 1:39 AM Last Resulted: 12/23/16 2:31 PM x+Reference range differ from displayed range	
^M Kalser Permanente.	
Refer to Genetics	
When in doubt, send a Dr. Advice to genetics.	
	1
What's the difference between alpha and beta thalassemia?	
beta thalassemia?	







Beta thalassemia


- Decreased production of β chains, increased α chains High levels of α chains damage bone marrow and decrease erythropoesis Higher levels of Hb A2
- Most common in people of Mediterranean, North African, and South-East Asian ancestry $\,$
- Variable severity depending on mutation and level of β chain production β^0 thalassemia no Hb A produced, more severe β^* thalassemia some Hb A produced, mild
- Similar symptoms and treatment as sickle cell disease
- Also called Cooley's anemia


Genetic Home Reference: Your quide to understanding genetic conditions. (2012) Weatherall DJI. Phenotype-genotype relationships in monogenic disease: lessons from the thalassemias. Nat Rev Genet. 2001

Alpha thalassemia trait							
	FRACTIONATION, CHRON Visible to patient: No (Not Relea		17 at 02:00 DM to Par	disting Openhous (MICH)	AEL DAVIMOND GIBUIGIA	N MO M O V De	
status, rmai result	visione to patient No (Not kelea			3,7	NEL PATRICIPO GIRVIGIA	er mu, nt.D.) UX	
				/11/17 12:28 PM			
HEMOGLOBIN A %,		%		5.7			
HEMOGLOBIN A2 %	6. HPLC	1.5 - 3	1.5 % 2.	7			
HEMOGLOBIN F %,	HPLC	<=2.0	96 0.	0.4			
HEMOGLOBIN PHEN	NOTYPE, BLOOD		A	A			
				memic or has sutritionally-response needed. In the	nsive anemia, no fu	rther testin	
Notes Recorded by Tusson, Ang Letter sent	offert: Yes (kgorg) Niest appt. 08/29/2017 at 03:00: gefica 5 (R.N.), R.N. on 8/8/2017 at 10:14 AM	PM in Radiation Crocology (MSCHAE), RJ	IYMOND GBYYSSAN MD, M.D.) C	N: ROUTINE ADULT HEALTH-CHECK UP	DAM		
WECKAUTO	Ref Range & Units 4.0 : 11.0 x1000 mus	8/7/17 9:39 AM	1/11/16 12:30 PM	12/24/15 5:55 AM	12/23/35 558 AM	12/15/15 8:39 4	
RBC, AUTO	4.0 - 11.0 x1000/mcs. 4.20 - 5.40 Millimst.	5.55 A	7.8 5.38	25.6 A	33.0 A	5.8	
HGB	420 - 540 Miljims, 12.0 - 16.0 4/6.	12.5	338 334 V	87 V	MV	107 V	
HCT, AUTO	37.0 - 47.0 %	29-0	365 W	29.0 ₩	30.7 V	35.6 ₩	
MCV	81.0 - 99.0 %	69.1 w	67.9 w	67.2 v	66.7 w	67.4 w	
	27.0 - 35.0 pg/cell	22.2 ₩	21.2 ❤	20.2 🕶	26.3 🕶	20.2 ₩	
MOH							
	32.0 - 37.0 g/dl. 11.5 - 14.5 %	12.1 14.7 A	31.2 V	18.8 △	38.4 ~	30.0 ♥	

ha thalassemia	ı trait	
sult. Visible to nation! Ves (kn own) Next ann!	00/29/2017 at 03:00 PM in Radiation Openion	y (MICHAEL RAYMOND GIRVIGIAN MD. M.D.) Dxx
unt visible to patient. Tes (kp.org) (Vext appt.	Ref Range & Units	9/11/17 12:28 P
	13 - 126 ng/mL ney disease and dialysis patients m	34
ND TIBC sult Visible to patient: Yes (kp.org) Next ap	pt: 09/29/2017 at 03:00 PM in Radiation Once	ology (MICHAEL RAYMOND GIRVIGIAN MD, N
	Ref Range & Units	9/11/17 12:28 PM
BINDING CAPACITY	37 - 145 mcg/dL 250 - 450 mcg/dL	177 ▲ 361
BINDING CAPACITY	20 - 50 %	49
		👫 KAISER PER


Previo	usly norr	nal MCV	1	
FERENTIAL t: No (Not Released) Next appl	t: 09/19/2017 at 10:00 AM in G	enetics (EMILY S PARKHURS	ST) Dx: ABNL VAGINAL BLEER	DING
	Newer result	s are available. Click to view	them now.	
Ref Range & Units 4.0 - 11.0 x1000/mcL	11/13/15 8:35 AM 6.1	10/12/14 5:14 AM 9.7	10/11/14 7:54 AM 8.1	7/17/14 11:41 A 9.4
4.20 - 5.40 Mill/mcL 12.0 - 16.0 g/dL	3.30 ¥	2.87 ¥ 7.6 ¥	3.90 ¥ 10.1 ¥	3.79 ¥ 10.6 ¥
o: N.ONTIVEROS RN 633 Read back of verba		med		
37.0 - 47.0 %	20.9 ❤	22.9 🕶	30.6 ❤	31.1 🗸
81.0 - 99.0 fL	63.3 🕶	80.0 🗸	78.4 🕶	82.1
27.0 - 35.0 pg/cell	18.4 ✔	26.6 ₩	25.9 ₩	28.0
32.0 - 37.0 g/dL	29.0 ✔	33.3	33.1	34.1
11.5 - 14.5 %	23.1 ^	14.5	13.9	13.5
130 - 400 x1000/mcL	257	128 🗸	135	195
	FERENTIAL 1: No (Not Released) Next app Ref Range & Units 40 - 11.0 ±000/mc. 4.0 - 3.0 Millimet. 310 - 160 g/d. 313	FERENTIAL No (Not falsesed) Nort appt 08/19/2017 at 1800 AM in G Never result Ref Range & Uvist. 40-110 / 1000/mcd. 41 40-1-540 / 1000/mcd. 43 120-140 / 1000/mcd. 43 130-10 / 10	FERENTIAL No (Not Released) Not appt 09/19/2017 at 1000 AM in Genetics (IMEV S PARIOLUM Never results are available. Cick to view 11/13/15 803 AM 10/12/14 514 AM 40/11/14 000/mcd. 41 97 40/11/14 000/mcd. 43 97 72/14 10/14 000/mcd. 43 97 72/14 10/14 000/mcd. 43 97 72/14 10/14/14 000/mcd. 44 97 5.80 AM 10/12/14 514 AM 40/11/14/14/14/14/14/14/14/14/14/14/14/14/	Note Note





α thalassemia There are four alpha globin genes in total. (aa / aa) • "Silent" carriers have 3 functional α genes (-a / aa) - Carriers have 2 functional α genes (-a / -a) (-- / aa) - Hb H disease due to only α gene (-- / -a). Hydrops fetalis/ Hb Barts no α genes (--/--). The lethal form of alpha thalassemia from hydrops fetalis due to two cis mutations, which is associated with Asian ancestry. KAISER PERMANENTE. How to tell thalassemia carriers apart? Low MCV <u>↑Hb A2</u> Normal Hb Beta thal trait · Iron deficiency Alpha thal trait KAISER PERMANENTE. Refer to Genetics When in doubt, send a Dr. Advice to genetics.

	-
	·
Benign hemoglobin traits	
	•
What are some benign hemoglobin variants?	
Hb A2' (or delta chain variant)	
TID AZ (OF GERTA CHAIIT VARIATIL)	
Tarrotan	
Elevated Hb F	
M KAISER PERMANENTE.	
Hb A2' /delta chain variant	
The A2' (also called A2 prime or a delta-chain variant) is not a hemoglobinopathy trait and does not affect health	
nemoglobinopatny trait and does not affect nearth	
* HEMOGLOBIN VARIANT CONFIRMATION, ELECTROPHORESIS	
Status: Final result Visible to patient: No (Not Released) Next appt: 10/09/2017 at 02:50 PM in Obstetrics, Gynecology (NICOLE NAM Ref Range & Units 8/25/17 2-52 PM	
HEMOGLOBIN PHENOTYPE, BLOOD AA HGB PHENOTYPE INTERPRETATION, BLOOD, HD AZ	
ELECTROPHORESIS No A2' (Also known as No B2). This patient has a delta-chain variant, most	
common among people of African or Sicilian descent. This is of no known hematologic consequence. Both MD A2 and MD A2' are included in the reported	
Mb A2 percentage.	
** KAISER PERMANENTE	



Hereditary Persistence of Fetal Hemoglobin

- Individuals with such deletions may have hereditary persistence of fetal hemoglobin (HPFH) with up to 35% Hb F in adults; this is a benign condition.
 - Hydroxyurea uses this mechanism to increase Hb F in blood to treat patients with sickle cell anemia and beta thalassemia
- A slight elevation in Hb F (3-5%) is not a hemoglobinopathy trait and is naturally associated with pregnancy.

Hered	itary Persister Hemoglobi		tal	
* HEMOGLOBIN EVALUATION			Order	
Status: Final result Visible to patient: No (N	ot Released) Next appt: None			
HEMOGLOBIN A %, HPLC	Ref Range & Units %	8/23/13 4:40 PM 93.4	Flag	
HEMOGLOBIN A2 %, HPLC	1.5 - 3.5 %	2.8		
HEMOGLOBIN F %, HPLC	<=2.0 %	2.1 ^	H	
HEMOGLOBIN PHENOTYPE, BLOOD		See above		
* HEMOGLOBIN EVALUATION Status: Final result Visible to patient: No (Not Release	ed) Next appt: None Dx: PRENATAL INTAKE INTERVIE	W 8/7/15 4:28 PM		Ord
HEMOGLOBIN A %, HPLC	%	90.5		rwy
HEMOGLOBIN A2 %, HPLC	1.5 - 3.5 %	2.4		
HEMOGLOBIN F %, HPLC	<=2.0 %	6.8 ^		H
HGB F INTERPRETATION, BLOOD, HPLC		presence of heredite persistence of fetal beta-thalassemia. : elevation can also : myeloproliferative : marrow failure. Up in normal patients :	hemoglobin (HPFH) of Isolated HbF scour with pregnancy, disorders, and to 10% Hb F can be :	or found
HEMOGLOBIN PHENOTYPE, BLOOD		SEE ABOVE		
		ė	[™] Kaiser Perm <i>i</i>	ANENTE.

Hereditary Persistence	of Fetal
Hemoglobin	
HEMOGLOBIN EVALUATION Status: Final result: Visible to patient: No (Not Released) Next appt: None Notes Recorded by Gogia, Raveen Kaur (M.D.) on 5/23/2012 at 9:30 AM Ref genetics sent. Ref Range & Units	5/17/12 1030 AM
HAMOGORNY 8, HPIC Commentic Levelated BD F. This pattern can occur in the presence of hereditary persistence of feral hemoglobul (BPR) or hete-chalasemia. Included BB F elevation can also coord with marror failure. Up to 10 Nb BP can be found	26.0 🔦
in normal patients 1-2 years of age, but Nb F rarely exceeds 2% thereafter. HEMOGLOBIN A.%, HPLC 1.5 - 3.5 % HEMOGLOBIN A.%, HPLC %	1.9 71.8
Specimen Collected: 05/17/12 10:30 AM Last Resulted: 05/21/12	1:39 PM
	KAISER PERMANENTE
011 1 1 5	
Clinical Recomme	ndations
	et.
	KAISER PERMANENTE.
Clinical Recommen	dations
	uatiUlis
CBC for all pregnant w	vomen or women planning
pregnancy. Hemoglobil of certain ethnicities (A	romen or women planning n electrophoresis in those African, Mediterranean, east Asian, West Indian)
Niliddle Eastern, South	east Asian, West Indian)
000 and Harry 111	avaluation for all
women, regardless of	evaluation for all pregnant ancestry
PERMÄNENTE _®	
ACOG Committee Opinion No. 691: Carrier Screening for Genetic Condi Regional SCAL Kaiser Permantete Genetics policy. April 2016	itions. Mar 2017 KAISER PERMANENTE

Hemoglobinopathy algorithm Complete blood count (CBC) and hemoglobin evaluation Beta Thal Trait (Low MCV and High Hb A2) Alpha Thal Trait Abnormal (Low MCV, Hemoglobin Eval (Hb AS, AC, AE) Normal Hb, High risk ancestry)* Test FOB with CBC, Hb Eval *Also serum iron studies as indicated KAISER PERMANENTE. Testing the partner/ FOB Kaiser will cover hemoglobinopathy screening for non-member FOBs If a pregnant patient is a carrier of a hemoglobinopathy, testing for the her partner (FOB) is a covered benefit and part of her prenatal care. There are no copays or cost sharing for him. - If the partner has an MRN from the past, we use that - Call MRN services to create a temporary Kaiser number for him KAISER PERMANENTE. Refer to Genetics When in doubt, send a Dr. Advice to genetics.

Counseling

KAISER PERMANENTE.

Health Care Disparities

Recent studies have shown that despite the improvements in the overall health of the country, racial and ethnic minorities experience a lower quality of health care—they are less likely to receive routine medical care and face higher rates of morbidity and mortality than nonminorities



KAISER PERMANENTE.

Health Care Disparities

Major findings on racial and ethnic gaps in health care

- Disparities in health care exist and are associated with worse health outcomes.
- Health care disparities occur in the context of broader inequality.
- There are many sources across health systems, providers, patients and managers that contribute to disparities.
- Bias, stereotyping, prejudice and clinical uncertainty contribute to disparities.
- A small number of studies suggest that racial and ethnic minority patients are more likely to refuse treatment.

Counseling issues

Medical literacy

- Use words patients will understand
- Many patients are visual learners
 - Show they the lab results
 - Draw a picture or a Punnett square
- Reinforce that the patient inherited the condition from a parent and that other family members (siblings) may also be carriers.
- Normalize/ reduce stigma
 - Emphasize that every populations has some genetic condition

KAISER PERMANENTE.

Counseling issues

Reluctant partners

- Validate concerns
 - Fear of needles, mistrust of doctors, health care disparities are real
 - Reassurance
- Review the facts
 - People who carry the trait feel fine. The only way to know is from a blood test.
- Encourage teamwork
 - It is only fair that if the woman had to get all these blood tests, he can do some too
 - Ultimately, it is his choice and he can refuse testing

M KAISER PERMANENTE.

Prenatal Diagnosis



CVS: 10-13 weeks



Aminocentesis: 15-20 weeks

Counseling issues

- CVS and amniocentesis is indicated when both parents are carriers
 - If the father is unavailable for testing, prenatal diagnosis is also indicated
- The patient has the option to continue or terminate an affected pregnancy
 - We support patients and families in what ever decision is right for them

KAISER PERMANENTE



KAISER PERMANENTE.


Status: Final result Visible to patient: Yes	(kp.org) Next appt: 11/01/2017 at 10:40 /	AM in Obstetrics, Gynecology (LATONYA	ROCHELLE BOTSHEKAN CNM
	Ref Range & Units	9/22/17 1:37 PM	2/28/17 3:00 PM
WBC'S AUTO	4.0 - 11.0 x1000/mcL	6.1	5.9
RBC, AUTO	4.20 - 5.40 Mill/mcL	4.45	4.56
HGB	12.0 - 16.0 g/dL	12.0	12.6
HCT, AUTO	37.0 - 47.0 %	36.2 ✔	37.6
MCV	81.0 - 99.0 fL	81.2	82.4
MCH	27.0 - 35.0 pg/cell	27.0	27.7
MCHC	32.0 - 37.0 g/dL	33.2	33.6
RDW, BLOOD	11.5 - 14.5 %	16.7 🔨	12.9
PLATELETS, AUTOMATED COUNT	130 - 400 x1000/mcL	220	163


* CBC W AUTOMATED DIFFERENTIAL


KAISER PERMANENTE.

Example 1 - sickle cell trait

19 year old female, African American G1P0









EXAMPLE 2 — beta thalassemia trait a 31 year old female patient, Asian East Indian CDC NO DIFFERENTIAL Solator Final result. Visible to patient: kg.org. Next appl: 68/11/2017 at 04:00 PM in Rhounautology (LYNNETTE TATOSYAN DO, D.O.) Dr. SUPPERVISC NOTES Recorded by Cogin, Reverse Natury (BLJ), BLD on EXTENDED 14 255 AM NOTES Recorded by Cogin, Reverse Natury (BLJ), BLD on EXTENDED 14 255 AM NOTES Recorded by Cogin, Reverse Natury (BLJ), BLD on EXTENDED 14 255 AM NOTES RECORDED 15 AM NOTES RECOR

		mple 2 - FOB Id male partner, Chinese ancestr	у
CBC NO DIFFERENTIAL Status: Final result Visible to	patient: kp.org	Next appt: None Dx: REPRODUCTIV	TE MGMT, MALE GENETIC TEST
		Ref Range	7/23/16 11:19 AM
WBC'S AUTO		4.0 - 11.0 x1000/mcL	5.7
RBC, AUTO		4.70 - 6.10 Mill/mcL	4.88
HGB		14.0 - 18.0 g/dL	15.0
HCT, AUTO		42.0 - 52.0 %	43.4
MCV		80.0 - 94.0 fL	89.0
MCH		27.0 - 35.0 pg/cell	30.8
MCHC		32.0 - 37.0 g/dL	34.6
RDW, BLOOD		11.5 - 14.5 %	12.8
PLATELETS, AUTOMATE		130 - 400 x1000imcL	179
inal result Visible to patient: Not Released		Dx: REPRODUCTIVE MGMT, MALE GENET 7/23/16 11:19 AM 96.0	C TESTI
MOGLOBIN A %, HPLC	15.35%	2.9	
MOGLOBIN F %, HPLC	<-20%	0.2	
MOGLOBIN PHENOTYPE, BLOOD		AA	
GB PHENOTYPE INTERPRETATION, BLOOD, H	PLC	context of microcytic anemia and seen in patients with alpha thala anemia and severe iron deficiency	atient is not anemic or has no further testing is needed. In ti normal iron studies, these results : ssemia. In the context of microcyti , beta thalassemia trait cannot be er reordering this test if the micr



LXuII	ıple 3 – beta thala	isscilla ti	ait
	31 year old female patient, Asian Ea	st Indian ancestry	
* CBC NO DIFFERENTIAL			
tatus: Final result Visible to patient: No (N	ot Released) Next appt: 10/19/2017 at 09:20 AM	in Obstetrics, Gynecology (JI	ENNIFER JEAN LEE MD, M.D.)
	Ref Range & Units		9/14/17 8:14 AM
WBC'S AUTO	4.0 - 11.0 x1000/mcL		5.4
RBC, AUTO	4.20 - 5.40 Mill/mcL		5.53 ^
HGB	12.0 - 16.0 g/dL		10.9 ✔
HCT, AUTO	37.0 - 47.0 %		34.8 ❤
MCV	81.0 - 99.0 fL		63.0 ✔
MCH	27.0 - 35.0 pg/cell		19.7 ✔
MCHC	32.0 - 37.0 g/dL		31.2 🕶
RDW, BLOOD	11.5 - 14.5 %		15.5 ^
PLATELETS, AUTOMATED COUNT	130 - 400 x1000/mcL		200
HEMOGLOBIN FRACTIONATION, CHRO	MATOGRAPHY		
atus: Final result Visible to patient: No (Not Released	l) Next appt: 10/19/2017 at 09:20 AM in Obstetrics, Gynecolo	ogy (JENNIFER JEAN LEE MD, M.D.)	Dx: ANTENATAL SCREENING
	Ref Range & Units	9/14/17 8:14 AM	
EMOGLOBIN A %, HPLC EMOGLOBIN A2 %, HPLC	% 15 - 3.5 %	91.5	
GB AZ INTERPRETATION, BLOOD, HPLC	13-33 %		ed. In the context of
		microcytic aner usually seen in thalassemia. He	ned. In the context or his, these results are hipatients with beta matology consultation is but reproductive counseling
EMOGLOBIN F %, HPLC	c=2.0%	1.7	

		34 year old male	e partner, Asian East Indian a	ncestry		
				nooday		
C NO DIFFERE	ENTIAL Visible to patient: kp.org	Next appt: None	Dx: GENETIC COUNSELING			2000
			Ref Range	2/10/17 4:15 PM	Flag	_
WBC'S AUTO			4.0 - 11.0 x1000/mcl.	7.5		
RBC, AUTO			4.70 - 6.10 Mill/mcL	6.63	(H)	
HGB			14.0 - 18.0 g/dL	13.6	(L)	
HCT, AUTO			42.0 - 52.0 %	42.1		
MCV			80.0 - 94.0 fL	63.5	(L)	
MCH			27.0 - 35.0 pg/tell	20.5	L	
MCHC			32.0 - 37.0 oldl.	32.3		
RDW, BLOOD			11.5 - 14.5 %	14.8	(H)	
PLATELETS.	AUTOMATED COUNT		130 - 400 x1000/mcl.	201		
	TIONATION, CHROMATOGR		NETIC COUNSELING			
	ble to patient: Not Released Ne Ref Ran		2/10/17 4:15 PM			÷
HEMOGLOBIN A %	Ref Ran	ge	2/10/17: 4:15 PM 93.4			
HEMOGLOBIN A N HEMOGLOBIN A 2	Ref Ran N, HPLC % N, HPLC 15-351	ge	2/10/17 4:15 PM 93.4 (4.8)			
HEMOGLOBIN A N HEMOGLOBIN A N HEMOGLOBIN A2 HGB A2 INTERPRE	, HPLC % %, HPLC 15-351 TATION, BLOOD, HPLC	ge	2710/17 4.15 PM 93.4 (4.8) No A2 is elevated. In the contex usually seen in patients with be not necessary, but reproductive	ta thalassemia. Hematolog	y consultation is	
HEMOGLOBIN A N HEMOGLOBIN A 2	i, HPLC % %, HPLC 15-351 ETATION, BLOOD, HPLC HPLC ~20%	ge	2/10/17 4:15 PM 90.4 (4.8) No A2 is elevated. In the contex usually seen in patients with be	ta thalassemia. Hematolog	y consultation is	



	ig regional genetics Laboratory Report# 389546 ECULAR GENETIC REPORT Page: 1
Name REB PORT POR	3/10/17 Specimen : CVS-direct
a carrier for	nosis of beta thalassemia. The mother of the fetus is the 610p deletion and the father is a carrier for variant within the MBB gene.
REPORT	
Test: DNA analysi	s of the Beta globin gene.
variant, c.92+	nalysis revealed the presence of a known pathogenic 10-7, within the HRB gene. The 619bp deletion was not is fetal sample.
within the HBE	a carrier for the c.92:10-T (beta 0) variant gene. The study for maternal cell was not performed based on this result.


	30 year old Mexican American G3P2	•
	30 year old Mexican American G3P2	
CBC NO DIFFERENTIAL Status: Final result Visible to patient: Yes (kp.org) Next appt: 10/14/2017 at 01:00 PM in Health Education	n (MEDYLINE BULANTE RN, R.N.) Dx: ANTI
		Newer results are available. C
WBC'S AUTO	Ref Range & Units 4.0 - 11.0 x1000/mcL	4/4/17 1:52 PM 6.2
RBC, AUTO	4.20 - 5.40 Mill/mcL	4.53
HGB	12.0 - 16.0 g/dL	11.0 🕶
HCT, AUTO	37.0 - 47.0 %	33.9 ✔
MCV	81.0 - 99.0 fL	74.9 🕶
MCH	27.0 - 35.0 pg/cell	24.2 ▼
MCHC	32.0 - 37.0 q/dL	32.4
RDW, BLOOD	11.5 - 14.5 %	16.3 ^
PLATELETS, AUTOMATED COUNT	130 - 400 x1000/mcL	238
EMOGLOBIN FRACTIONATION, CHROMATO stus: Final result Visible to patient: No (Not Released) !	DGRAPHY Next appt: 10/14/2017 at 01:00 PM in Health Education (MEDY)	INE BULANTE RN, R.N.) Dx: ANTENATAL SCREE
	Ref Range & Units	4/4/17 1:52 PM
EMOGLOBIN A %, HPLC	%	95.8
MOGLOBIN A2 %, HPLC MOGLOBIN F %, HPLC	1.5 · 3.5 % < =2.0 %	2.8
MOGLOBIN F %, HPLC MOGLOBIN PHENOTYPE, BLOOD	<=2.0 %	0.2 AA
GB PHENOTYPE INTERPRETATION, BLOOD, HPLC		No abnormality dete

	ole 5 – alpha tha 24 year old African Am		it
CBC NO DIFFERENTIAL Status: Final result Visible to patient: Yes	(kp.org) Next appt: None Dx: ROUTINE ADUI	LT HEALTH CHECK UP EXAM	
Notes Recorded by Tuason, Angelica S (F Letter sent Notes Recorded by Zheng, Xiaona (M.D.) Call or letter - Blood test is normal no me	, M.D. on 8/7/2017 at 6:48 PM		
Call or letter - Blood test is normal, no mo	Ref Range & Units	8/7/17 9:59 AM	1/13/16 12:30 PM
WBC'S AUTO	4.0 - 11.0 x1000/mcL	5.5	7.8
RBC, AUTO	4.20 - 5.40 Mill/mcL	5.65 🔦	5.38
HGB	12.0 - 16.0 g/dL	12.5	11.4 🗸
HCT, AUTO	37.0 - 47.0 %	39.0	36.5 ✔
MCV	81.0 - 99.0 fL	69.1 🗸	67.9 🗸
мсн	27.0 - 35.0 pg/cell	22.2 🕶	21.2 🕶
мснс	32.0 - 37.0 g/dL	32.1	31.2 🕶
RDW, BLOOD	11.5 - 14.5 %	14.7 ^	18.9 ^
PLATELETS, AUTOMATED COUNT	130 - 400 x1000/mcL	222	293
HEMOGLOBIN FRACTIONATION, CH Status: Final result Visible to patient: No (Not	ROMATOGRAPHY Released) Next appt: None Dx: THALASSEMIA: SCF Ref Range & Units 66	REENING FOR GENETIC DL	9/11/17 12:28 PM 95.7
HEMOGLOBIN A %, HPLC HEMOGLOBIN A2 %, HPLC HEMOGLOBIN F %, HPLC HEMOGLOBIN PHENOTYPE, BLOOD	1.5 - 3.5 % <=2.0 %		2.7 0.4 AA

	5 – alpha thalassemia year old African American G2P1	a trait
* IRON AND TIBC Status: Final result Visible to patient: Yes (kp.or.	as Newtonest Mone Co. THAI ASSEMIA	
Status. Pinal result. Visible to patient res (xp.or	Ref Range & Units	9/11/17 12:28 PM
IRON	37 - 145 mcg/dL	177 A
TOTAL IRON BINDING CAPACITY	250 - 450 mcq/dL	361
IRON SAT	20 - 50 %	49
FERRITIN Status: Final result Visible to patient: Yes (kp.or	Next aget: Mone Por THALASSEMIA	
Status. Pinal result. Visible to patient res (kp.or	Ref Range & Units	9/11/17
FERRITIN	13 - 126 ng/mL	34
	hronic kidney disease and dialysis patients may n levels between 100 and 1200 ng/ml.	be
	-American. Since the couple is not of a high ed for hemoglobinopathy. iron supplements	risk ancestry, the
		M KAISER PERMANENTE.

	e 6 – Hb C trait 2 African-American woma	an
† HEMOGLOBIN VARIANT CONFIRMATION, E		
Status: Final result Visible to patient: No (Not Released) No		
HEMOGLOBIN A.BLD.ON. ELECTROPHORESIS	Ref Range & Units	12/21/16 11:39 AM 59.6
HGB C %, BLOOD, ELECTROPHORESIS	70	36.8
HEMOGLOBIN PHENOTYPE, BLOOD	AA	AC 1
HGB PHENOTYPE INTERPRETATION, BLOOD, ELECTROPHO Meterozygous Nb C (Nb C Trait). This is a c does not produce anemia. Hematology consul reproductive counseling may be advisable. 2 Mb F elevations may indicate the presence	clinically benign condition which itation is not necessary, but Anemia, preponderance of Hb C and	Heterozygous Hb C (
Narrative		
RMS ACCN: 598936625 Specimen Collected: 12/21/16 11:39 AM R=Reference range differs from displayed range	Last Resulted: 12/23/16 2:31 PM	
	ė	M KAISER PERMANENTE.

HEMOGLOBIN FRACTIONATION, CHROMA		
tatus: Final result Visible to patient: No (Not Released	 Next appt: None Dx: REPRODUCTIVE MGMT, MALE GENETIC T 	
HEMOGLOBIN A %. HPLC	Ref Range & Units	8/30/17 2:04 PM
HEMOGLOBIN A %, HPLC HEMOGLOBIN A2 %, HPLC	15 - 3.5 %	95.9 2.7
HEMOGLOBIN AZ %, HPLC	<=2.0 %	0.2
HEMOGLOBIN PHENOTYPE, BLOOD		AA
HGB PHENOTYPE INTERPRETATION, BLOOD, HPLC		
* CBC NO DIFFERENTIAL	eleased) Next appt: None Dx: REPRODUCTIVE MGMT, MAI	LE GENETIC TESTI
CBC NO DIFFERENTIAL Status: Final result Visible to patient: No (Not Re WBC'S AUTO	Ref Range & Units 4.0 - 11.0 x1000/mcL	LE GENETIC TESTL 8/30/17 2:04 PM 4.2
CBC NO DIFFERENTIAL Status: Final result Visible to patient: No (Not Re WBC'S AUTO RBC, AUTO	Ref Range & Units 4.0 - 11.0 x1000/mcL 4.70 - 6.10 Mill/mcL	8/30/17 2:04 PM 4.2 5.75
CBC NO DIFFERENTIAL Status: Final result Visible to patient: No (Not Re WBC'S AUTO	Ref Range & Units 4.0 - 11.0 x1000/mcL	LE GENETIC TESTL 8/30/17 2:04 PM 4.2
CBC NO DIFFERENTIAL Totalius: Final result Visible to patient: No (Not Re WBC'S AUTO RBC, AUTO HGB HGT, AUTO	Ref Range & Units 4.0 - 11.0 x1000/mcL 4.70 - 6.10 Mill/mcL 140 - 18.0 g/dL 42.0 - 52.0 %	8/30/17 2:04 PM 42 5:75 13:4 ¥
CBC NO DIFFERENTIAL Totalius: Final result Visible to patient: No (Not Re WBC'S AUTO RBC, AUTO HGB HGT, AUTO	Ref Range & Units 4.0 - 11.0 x1000/mcL 4.70 - 6.10 Mill/mcL 14.0 - 18.0 g/dL	8/30/17 2:04 PM 42 5.75 13.4 ¥
CBC NO DIFFERENTIAL Status: Final result Visible to patient: No (Not Re WBC'S AUTO RBC, AUTO HGB	Ref Range & Units 4.0 - 11.0 x1000/mcL 4.70 - 6.10 Mill/mcL 140 - 18.0 g/dL 42.0 - 52.0 %	8/30/17 2:04 PM 42 5:75 13:4 ¥
CBC NO DIFFERENTIAL Itatus: Final result Visible to patient: No (Not Re WBCS AUTO RBC, AUTO HGB HGT, AUTO MCV MCV	Ref Range & Units 4.0 - 11.0 x1000/mcL 4.70 - 6.10 k10/mcL 14.0 - 18.0 g/dL 42.0 - 52.0 % 80.0 - 94.0 fL	8/30/17 2:04 PM 42 5:75 13:4 × 41.7 × 72:5 ×
CBC NO DIFFERENTIAL Total result: Voibble to patient: No (Not Re WBCS AUTO NBBC AUTO NBBC MTO MCV MCV MCW MCM MCM MCM MCM MCM MCM MCM MCM MCM	Ref Range & Units 4.0 - 1.10 xt000/mcl 4.70 - 6.10 Mill/mcl 14.0 - 18.0 g/dl 42.0 - 52.0 % 80.0 - 94.0 ft 27.0 - 35.0 pg/cell	8/30/17 2-04 PM 42 5.75 13.4 × 41.7 × 72.5 v 23.3 v



		mple 7 – HPFH 2P1 European-American	woman	
	FRACTIONATION, CHROMATOGRA			
tatus: Final result Vis	ible to patient: No (Not Released) Next appt: I			
HEMOGLOBIN A %. HI	PLC .	Ref Range & Units		8/25/17 3:17 PM 72.6
EMOGLOBIN A2 %. F	HPLC	1.5 - 3.5 %		2.2
EMOGLOBIN F %, HF		<=2.0 %		25.5 A Elevated Hb F. Th
persistence of				
marrow failure. of age, but Hb HEMOGLOBIN PHENO	CBC NO DIFFERENTIAL		MAL PREGNANCY, THIRD T	SEE ABOVE
marrow failure. of age, but Hb HEMOGLOBIN PHENO	. Up to 10% Mb F can be found in r F rarely exceeds 2% thereafter. DTYPE BLOOD CBC NO DIFFERENTIAL	ormal patients 1-2 years	MAL PREGNANCY, THIRD T 4/21/16 11:	
elevation can a marrow failure. of age, but Hb IEMOGLOBIN PHENO State	. Up to 10% Mb F can be found in r F rarely exceeds 2% thereafter. DTYPE BLOOD CBC NO DIFFERENTIAL	ormal patients 1-2 years up.org) Next appt: None Dx: SUPERVISION NORM		
elevation can a marrow failure of age, but Hb EMOGLOBIN PHENC	. Up to 10% ND F can be found in r F rarely exceeds 2% thereafter. STYPE, BLOOD CBC NO DIFFERENTIAL us: Final result Visible to patient: Yes (8	rormal patients 1-2 years roorg) Next appt: None Dx: SUPERVISION NORM Ref Range & Units	4/21/16 11:	
elevation can a marrow failure of age, but Hb EMOGLOBIN PHENC	. Op so 104 No F can be found in r F sarely exceeds 24 thereafter. OFFICE NO DIFFERENTIAL us: Final result Visible to patient Yes (8 CCS AUTO AUTO	ionemal patients 1-2 years (p.org) Next appt: None Dx: SUPERVISION NORM Ref Range & Units 4.0 - 11.0 x1000/mcl.	4/21/16 11: 9.9	
elevation can a marrov failure of age, but 8b EMOGLOBIN PHENO State WB RBC HGE	. Op so 104 No F can be found in r F sarely exceeds 24 thereafter. OFFICE NO DIFFERENTIAL us: Final result Visible to patient Yes (8 CCS AUTO AUTO	opmai patiente 1-2 years sporg) Next appt: None Dx: SUPERVISION NORM Ref Range & Units 4.0 - 11.0 x1000/mcl. 4.20 - 5.40 Mil/mcl.	4/21/16 11: 9.9 4.24	
elevation can a marrov failure of age, but 8b EMOGLOBIN PHENO State WB RBC HGE	. Op to 104 Nb F can be found in F F rately exceed 24 thereafter. TYPE ROOD CBC NO DIFFERENTIAL Use Final result Visible to patient Yes (I CS AUTO L. AUTO B. R. AUTO	opmai patients 1-2 years up.org) Next appt: None Dr. SUPERVISION NORM Ref Range & Units 4.0 - 1.1.0 x1000/mcl. 4.20 - 5.40 Mill/mcl. 12.0 - 16.0 g/dl.	4/21/16 11: 9.9 4.24	
elevation can a marrow failure. of age, but seem of age, and age of age of age, and age, age, and age, age, and age, age, age, age, age, age, age, age,	. Op to 104 To F cash be found in F frantly exceeded 24 thereafter. FIFTHELEON CERC NO DIFFERENTIAL Loss Final result Visible to patient. Yes (ICCS AUTO AUTO AUTO , AUTO , UNITO	openal patients 1-2 years (poorg) Next appt. None Dx: SUPERVISION NORM Ref Range & Units 40 - 110 1000mmc, 420 - 540 Mill/mct, 120 - 160 grd, 370 - 470 %	4/21/16 11: 9.9 4.24 11.5 ¥ 35.0 ¥	
elevation can a marrow failure. marrow failure. for age, but th teMOGLOEIN PHENO WB RBC HGE HGI HCT MC	. Op to 10% To F cash be found in it. F rankly exceeded 24 thereafter. TOPE LEGOD CES NO DIFFERENTIAL US: Final result Visible to patient. Yes (I CS AUTO AUTO V H H	opmel patients 1-2 years app.org) Nest appt None Dr. SUPERVISION NORM Ref Range & Units 4.0 - 11.0 x1000/mct, 4.20 - 1.60 yelf, 120 - 1.60 yelf, 370 - 47.0% 81.0 - 99.0 ft,	4/21/16 11: 9.9 4.24 11.5 ∨ 35.0 ∨ 82.4	
elevation can a marrow failure of age, but its temporary failure of age, but its failure failu	. Op to 10% To F cash be found in it. F rankly exceeded 24 thereafter. TOPE LEGOD CES NO DIFFERENTIAL US: Final result Visible to patient. Yes (I CS AUTO AUTO V H H	patients 1-2 years (p.org) Next appt. None Dr. SUPERVISION NORM Ref Range & Units A0 - 11.0 1000mmc, 4.20 - 5.40 Mill/mic, 120 - 140 grd, 370 - 47.0 % 61.0 - 99.0 ft, 770 - 15.50 pg/cell	4/21/16 11: 9.9 4.24 11.5 × 35.0 × 82.4 27.2	

